JP2005097319A5 - - Google Patents

Download PDF

Info

Publication number
JP2005097319A5
JP2005097319A5 JP2004347900A JP2004347900A JP2005097319A5 JP 2005097319 A5 JP2005097319 A5 JP 2005097319A5 JP 2004347900 A JP2004347900 A JP 2004347900A JP 2004347900 A JP2004347900 A JP 2004347900A JP 2005097319 A5 JP2005097319 A5 JP 2005097319A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004347900A
Other languages
Japanese (ja)
Other versions
JP2005097319A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005097319A publication Critical patent/JP2005097319A/ja
Publication of JP2005097319A5 publication Critical patent/JP2005097319A5/ja
Withdrawn legal-status Critical Current

Links

JP2004347900A 1993-05-12 2004-11-30 C型肝炎ウイルスe2/ns1領域の保存モチーフ Withdrawn JP2005097319A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6525508A Division JPH08510240A (ja) 1993-05-12 1994-05-03 C型肝炎ウイルスe2/ns1領域の保存モチーフ

Publications (2)

Publication Number Publication Date
JP2005097319A JP2005097319A (ja) 2005-04-14
JP2005097319A5 true JP2005097319A5 (enExample) 2005-11-04

Family

ID=22037528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP6525508A Pending JPH08510240A (ja) 1993-05-12 1994-05-03 C型肝炎ウイルスe2/ns1領域の保存モチーフ
JP2004347900A Withdrawn JP2005097319A (ja) 1993-05-12 2004-11-30 C型肝炎ウイルスe2/ns1領域の保存モチーフ
JP2005152406A Withdrawn JP2005325126A (ja) 1993-05-12 2005-05-25 C型肝炎ウイルスe2/ns1領域の保存モチーフ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP6525508A Pending JPH08510240A (ja) 1993-05-12 1994-05-03 C型肝炎ウイルスe2/ns1領域の保存モチーフ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005152406A Withdrawn JP2005325126A (ja) 1993-05-12 2005-05-25 C型肝炎ウイルスe2/ns1領域の保存モチーフ

Country Status (7)

Country Link
US (6) US6692907B1 (enExample)
EP (2) EP0697888B1 (enExample)
JP (3) JPH08510240A (enExample)
AT (1) ATE249838T1 (enExample)
CA (1) CA2162557C (enExample)
DE (1) DE69433160T2 (enExample)
WO (1) WO1994026306A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション C型肝炎ウイルスe2/ns1領域の保存モチーフ
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
ATE555794T1 (de) * 2000-02-14 2012-05-15 Mitsubishi Tanabe Pharma Corp Heilmittel gegen hepatitis
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039948A (en) 1973-05-07 2000-03-21 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4517304A (en) * 1980-07-01 1985-05-14 National Research Development Corporation Production of viral antigens
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
EP0318216B2 (en) 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
CA2017157C (en) 1989-05-18 2003-07-29 Michael Houghton Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
RO115446B1 (ro) * 1990-11-08 2000-02-28 Chiron Corp Procedeu de obtinere a asialoglicoproteinelor purificate provenind de la virusul hepatitei c
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
HU227547B1 (en) 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
ATE228564T1 (de) 1991-09-13 2002-12-15 Chiron Corp Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
WO1993016126A1 (fr) 1992-02-05 1993-08-19 Daikin Industries, Ltd. Polytetrafluoroethylene pulverulent destine au moulage
ES2287969T3 (es) 1992-03-06 2007-12-16 Innogenetics N.V. Peptidos de vih.
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション C型肝炎ウイルスe2/ns1領域の保存モチーフ
CA2175692A1 (en) 1993-11-04 1995-05-11 Geert Leroux-Roels Immunodominant human t-cell epitopes of hepatitis c virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE60125240T3 (de) * 2000-06-15 2010-10-28 Novartis Vaccines and Diagnostics, Inc., Emeryville Hcv-antigen/antikörper-kombinations-assay

Similar Documents

Publication Publication Date Title
BE2024C508I2 (enExample)
BE2023C542I2 (enExample)
BE2022C549I2 (enExample)
BE2021C001I2 (enExample)
BE2020C513I2 (enExample)
BE2020C517I2 (enExample)
BE2019C540I2 (enExample)
BE2019C523I2 (enExample)
BE2019C548I2 (enExample)
BE2019C506I2 (enExample)
BE2018C045I2 (enExample)
BE2020C525I2 (enExample)
BE2017C063I2 (enExample)
BE2017C027I2 (enExample)
BE2017C023I2 (enExample)
BE2017C002I2 (enExample)
BE2016C067I2 (enExample)
BE2016C014I2 (enExample)
BE2015C041I2 (enExample)
BE2015C038I2 (enExample)
BE2015C014I2 (enExample)
BE2014C071I2 (enExample)
BE2015C015I2 (enExample)
BE2014C064I2 (enExample)
BE2014C063I2 (enExample)